Anti-Aβ globulomer 7C6 antibodies

US9540432B2 · kind B2 · utility

Assignees

• Abb Vie Deutschland Gmbh & Co. KG · DE
• Abb Vie Inc. · US

Inventors

• Stefan Barghorn · Mannheim, DE
• Heinz Hillen · Herbrechtingen, DE
• Boris Labkovsky · Framingham, US
• Andreas Striebinger · Speyer, DE
• Patrick Keller · Darmstadt, DE
• Ulrich Ebert · Mannheim, DE

Key dates

• Filing date: May 14, 2013
• Grant date: Jan 10, 2017
• Expiry date: Oct 3, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/387
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Anti-Aβ globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies.The present invention relates to anti-Aβ globulomer antibodies having a binding affinity to Aβ(20-42) globulomer that is greater than the binding affinity of the antibody to Aβ(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.